Drugs / Oxidized regenerated cellulose
Oxidized regenerated cellulose
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05851560 | May → Sep 2023 | goiter, thyroid cancer | National Taiwan University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxidized regenerated cellulose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05851560 ↗ |
| Known as | Interceed | “patients undergoing thyroidectomy were randomized 1 : 1 : 1 to receive oxidized regenerated cellulose (Interceed™), high molecular weight hyaluronic acid (HANBIO BarriGel), or...” PMID 40613790 ↗ Jul 2025 |
| Known as | ORC | “Oxidized regenerated cellulose(ORC)” NCT05851560 ↗ |